Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 117(22): 12029-12040, 2020 06 02.
Article in English | MEDLINE | ID: mdl-32404427

ABSTRACT

Hutchinson-Gilford progeria syndrome (HGPS) is a uniformly fatal condition that is especially prevalent in skin, cardiovascular, and musculoskeletal systems. A wide gap exists between our knowledge of the disease and a promising treatment or cure. The aim of this study was to first characterize the musculoskeletal phenotype of the homozygous G608G BAC-transgenic progeria mouse model, and to determine the phenotype changes of HGPS mice after a five-arm preclinical trial of different treatment combinations with lonafarnib, pravastatin, and zoledronic acid. Microcomputed tomography and CT-based rigidity analyses were performed to assess cortical and trabecular bone structure, density, and rigidity. Bones were loaded to failure with three-point bending to assess strength. Contrast-enhanced µCT imaging of mouse femurs was performed to measure glycosaminoglycan content, thickness, and volume of the femoral head articular cartilage. Advanced glycation end products were assessed with a fluorometric assay. The changes demonstrated in the cortical bone structure, rigidity, stiffness, and modulus of the HGPS G608G mouse model may increase the risk for bending and deformation, which could result in the skeletal dysplasia characteristic of HGPS. Cartilage abnormalities seen in this HGPS model resemble changes observed in the age-matched WT controls, including early loss of glycosaminoglycans, and decreased cartilage thickness and volume. Such changes might mimic prevalent degenerative joint diseases in the elderly. Lonafarnib monotherapy did not improve bone or cartilage parameters, but treatment combinations with pravastatin and zoledronic acid significantly improved bone structure and mechanical properties and cartilage structural parameters, which ameliorate the musculoskeletal phenotype of the disease.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Disease Models, Animal , Lamin Type A/genetics , Progeria , Aging/drug effects , Aging/pathology , Animals , Bone and Bones/drug effects , Bone and Bones/pathology , Cartilage/drug effects , Cartilage/pathology , Femur/drug effects , Femur/pathology , Glycosaminoglycans/analysis , Joints/drug effects , Joints/pathology , Lamin Type A/metabolism , Mice , Mice, Transgenic , Mutation , Osteoarthritis/drug therapy , Osteoarthritis/pathology , Phenotype , Piperidines/therapeutic use , Pravastatin/therapeutic use , Progeria/drug therapy , Progeria/genetics , Protein Processing, Post-Translational/drug effects , Pyridines/therapeutic use , X-Ray Microtomography , Zoledronic Acid/therapeutic use
2.
Clin Nutr ; 38(5): 2145-2154, 2019 10.
Article in English | MEDLINE | ID: mdl-30224305

ABSTRACT

BACKGROUND & AIMS: Altering the lipid component in diets may affect the incidence of metabolic bone disease in patients dependent on parenteral nutrition. Consumption of polyunsaturated fatty acids (PUFA) can impact bone health by modulating calcium metabolism, prostaglandin synthesis, lipid oxidation, osteoblast formation, and osteoclastogenesis. The aim of this study was to evaluate the dietary effects of PUFA on murine bone health. METHODS: Three-weeks-old male (n = 30) and female (n = 30) C57BL/6J mice were randomized into one of three dietary groups. The diets differed only in fat composition: soybean oil (SOY), rich in ω-6 PUFA; docosahexaenoic acid alone (DHA), an ω-3 PUFA; and DHA with arachidonic acid, an ω-6 PUFA, at a 20:1 ratio (DHA/ARA). After 9 weeks of dietary treatment, femurs were harvested for micro-computed tomographic analysis and mechanical testing via 3-point bending. Separate mice from each group were used solely for serial blood draws for measurement of biomarkers of bone formation and resorption. RESULTS: At the microstructural level, although some parameters in cortical bone reached differences that were statistically significant in female mice, these were too small to be considered biologically relevant. Similarly, trabecular bone parameters in male mice were statistically different in some dietary groups, although the biological interpretation of such subtle changes translate into a lack of effect in favor of any of the experimental diets. No differences were noted at the mechanical level and in blood-based biomarkers of bone metabolism across dietary groups within gender. CONCLUSIONS: Subtle differences were noted at the bones' microstructural level, however these are likely the result of random effects that do not translate into changes that are biologically relevant. Similarly, differences were not seen at the mechanical level, nor were they reflected in blood-based biomarkers of bone metabolism. Altogether, dietary consumption of PUFA do not seem to affect bone structure or metabolism in a healthy model of growing mice.


Subject(s)
Cancellous Bone , Fatty Acids, Omega-3 , Femur , Animals , Bone Density/drug effects , Cancellous Bone/chemistry , Cancellous Bone/cytology , Cancellous Bone/drug effects , Cancellous Bone/physiology , Diet , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-3/pharmacology , Female , Femur/chemistry , Femur/drug effects , Femur/physiology , Male , Mice , Mice, Inbred C57BL , Weight Gain
SELECTION OF CITATIONS
SEARCH DETAIL